Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus.

from Breaking World Pharma News https://ift.tt/kGfRdmx